GC012F (AZD0120)

A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
18 patients (estimated)
Sponsors
AstraZeneca
Tags
CAR T Cell, B-Cell Maturation Antigen (BCMA), CD19, High Risk, Monotherapy, Open Label, Single Cohort
Trial Type
Treatment
Last Update
2 days ago
SparkCures ID
2146
NCT Identifier
NCT07073547

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.